Analyst Ratings For Acorda Therapeutics Inc (NASDAQ:ACOR)
Today, HC Wainwright reiterated its Buy rating on Acorda Therapeutics Inc (NASDAQ:ACOR) with a price target of $30.00.
There are 9 Hold Ratings, 3 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Acorda Therapeutics Inc (NASDAQ:ACOR) is Hold with a consensus target price of $23.0909 per share, a potential 18.66% upside.
Some recent analyst ratings include
- 11/5/2018-Acorda Therapeutics Inc (NASDAQ:ACOR) had its Buy rating reiterated by HC Wainwright with a $30.00 price target
- 11/4/2018-Acorda Therapeutics Inc (NASDAQ:ACOR) had its Hold rating reiterated by Jefferies Financial Group with a $22.00 price target
- 8/2/2018-Acorda Therapeutics Inc (NASDAQ:ACOR) had its Buy rating reiterated by Cowen with a $30.00 price target
- On 10/11/2018 Scopia Capital Management Lp, Major Shareholder, sold 143,576 with an average share price of $16.98 per share and the total transaction amounting to $2,437,920.48.
- On 10/9/2018 Scopia Capital Management Lp, Major Shareholder, sold 153,858 with an average share price of $17.28 per share and the total transaction amounting to $2,658,666.24.
- On 10/4/2018 Scopia Capital Management Lp, Major Shareholder, sold 126,464 with an average share price of $19.15 per share and the total transaction amounting to $2,421,785.60.
- On 10/2/2018 Scopia Capital Management Lp, Major Shareholder, sold 32,649 with an average share price of $18.89 per share and the total transaction amounting to $616,739.61.
- On 9/6/2018 Scopia Capital Management Lp, Major Shareholder, sold 13,829 with an average share price of $27.82 per share and the total transaction amounting to $384,722.78.
- On 9/4/2018 Scopia Capital Management Lp, Major Shareholder, sold 200 with an average share price of $29.00 per share and the total transaction amounting to $5,800.00.
- On 8/28/2018 Scopia Capital Management Lp, Major Shareholder, sold 20,256 with an average share price of $29.41 per share and the total transaction amounting to $595,728.96.
About Acorda Therapeutics Inc (NASDAQ:ACOR)
Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Recent Trading Activity for Acorda Therapeutics Inc (NASDAQ:ACOR)
Shares of Acorda Therapeutics Inc closed the previous trading session at 19.46 −0.72 3.57% with shares trading hands.